Overall, although preliminary data support a certain degree of renoprotection by DPP-4 inhibitors in T2DM-associated kidney disease, controversies remain, and large-scale, multicenter randomized controlled trials with renal outcomes as the primary endpoint are needed to further establish their long-term efficacy. The gene discussed is DPP4; the disease is kidney disorder.